Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)

Completed · Phase 2 · Has a placebo group

Conditions studied: Hepatitis C Infection

In brief

The purpose of this study is to identify 1 or more doses of daclatasvir, which when used in combination with pegylated interferon alpha and ribavirin, are safe and demonstrate sufficient anti-hepatitis C virus activity.

Key facts

Study ID

NCT00874770

Run by

Bristol-Myers Squibb

People needed

74

Starts

2009-06-01

Expected to finish

2011-01-01

Last updated by the study team

2015-10-23

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Alabama Liver & Digestive Specialists (Alds) — Montgomery, Alabama, United States
• University Of Colorado Denver & Hospital — Aurora, Colorado, United States
• Yale University School Of Medicine — New Haven, Connecticut, United States
• Mercy Medical Center — Baltimore, Maryland, United States
• Llc Dba The Research Institute — Springfield, Massachusetts, United States
• Veterans Affairs Medical Center — The Bronx, New York, United States
• Carolinas Center For Liver Disease — Statesville, North Carolina, United States
• Options Health Research, Llc — Tulsa, Oklahoma, United States
• Healthcare Research Consultants — Tulsa, Oklahoma, United States
• North Texas Research Institute — Arlington, Texas, United States
• Metropolitan Research — Fairfax, Virginia, United States
• Local Institution — Créteil, France
• Local Institution — Paris, France
• Local Institution — Vandœuvre-lès-Nancy, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.